Rasagiline Mesylate Transdermal Patch for Stable Amorphous Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing transdermal patches for rasagiline suffer from unideal absorption efficacy, instability, and difficulty in long-term storage due to rasagiline's instability in alkaline environments as a free base and issues with drug precipitation.
Innovation Solution
A transdermal patch formulation using rasagiline mesylate carried in a water-insoluble carrier, specifically employing crospovidone as a drug carrier with a matrix layer containing rasagiline mesylate, crospovidone, a binder, penetration enhancer, plasticizer, and antioxidant, forming a hydrogen bond complex to maintain the drug in an amorphous state and prevent crystallization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If rasagiline free base is carried in polyacrylate pressure-sensitive adhesives, silicone pressure-sensitive adhesives or polyvinyl alcohol under weakly alkaline conditions, then transdermal administration can be achieved, but drug content declines rapidly with complete degradation and high instability
Solution Approach 1:
The patent changes the chemical form of rasagiline from free base to mesylate salt, and adjusts the pH from weakly alkaline to acidic range (3-6). This parameter change fundamentally resolves the stability issue while maintaining transdermal delivery capability, as rasagiline mesylate remains stable in the acidic matrix environment
Solution Approach 2:
The patent uses a composite matrix system combining rasagiline mesylate with polyacrylate pressure-sensitive adhesive at controlled pH 3-6. This composite formulation maintains drug stability while enabling transdermal administration, overcoming the degradation issue of free base rasagiline in alkaline conditions
2Ease of operation
If rasagiline is formulated as free base in existing transdermal patches, then transdermal permeation can be achieved, but the drug is difficult to remain stable for long-term storage
Solution Approach 1:
The patent converts rasagiline from free base form to mesylate salt form and formulates in an acidic matrix (pH 3-6). This parameter change protects the drug during long-term storage by preventing degradation of the R-NH-C≡CH bond, while still allowing effective transdermal permeation upon application
3Ease of operation
If high pH is used in transdermal patch formulation, then transdermal absorption can occur, but rasagiline mainly exists as free base which is unstable and degrades
Solution Approach 1:
The patent inverts the conventional approach by using acidic pH (3-6) instead of alkaline pH. This parameter change stabilizes rasagiline mesylate in the matrix while maintaining transdermal absorption capability, as the acidic environment prevents hydrolysis of the drug molecule
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation ensures stable drug delivery without crystallization or precipitation, achieving high drug loading and bioavailability, with ideal transdermal effect and cumulative permeation of 20-100 µg/cm² over 24 hours, improving patient compliance and comfort.
Implementation Method 1
forming a hydrogen bond complex to maintain the drug in an amorphous state and prevent crystallization
Implementation Method 2
transdermal administration delivers drugs directly into blood circulation
Implementation Method 3
penetration enhancer
Data Source
Figure 1~2
Figure 3~4
AI summary
A transdermal patch comprising ransagiline mesylate and a preparation method therefor. A hydrogen bond complex is formed by means of the combined action of ransagiline mesylate, crospovidone and a crystallization inhibitor, so that ransagiline mesylate is present in a drug carrier in an amorphous state, thereby avoiding an unstable form of a free base. The transdermal patch further comprises a release-promoting agent selected from one or more of levulinic acid, octanoic acid and undecylenic acid.